Literature DB >> 21835173

Anti-inflammatory therapies in cancer cachexia.

Josep M Argilés1, Sílvia Busquets, Francisco J López-Soriano.   

Abstract

Disease progression in cancer is dependent on the complex interaction between the tumor and the host inflammatory response. Indeed, both the tumor and the patient produce cytokines that act on multiple target sites such as bone marrow, myocytes, hepatocytes, adipocytes, endothelial cells and neurons, where they produce a complex cascade of biological responses leading to the wasting associated with cachexia. The cytokines that have been involved in this cachectic response are TNF-alpha, IL-1, IL-6 and interferon-gamma. Interestingly, these cytokines share the same metabolic effects and their activities are closely interrelated. In many cases these cytokines exhibit synergic effects when administered together. Therefore, therapeutic strategies - either nutritional or pharmacological - have been based on either blocking their synthesis or their action.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835173     DOI: 10.1016/j.ejphar.2011.07.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Molecular characterization of skin microbiota between cancer cachexia patients and healthy volunteers.

Authors:  Wei Li; Lei Han; Pengbo Yu; Chaofeng Ma; Xiaokang Wu; John E Moore; Jiru Xu
Journal:  Microb Ecol       Date:  2014-01-09       Impact factor: 4.552

Review 2.  Pharmacology of manipulating lean body mass.

Authors:  Patricio V Sepulveda; Ernest D Bush; Keith Baar
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

Review 3.  Osteoporosis in chronic inflammatory disease: the role of malnutrition.

Authors:  Tiziana Montalcini; Stefano Romeo; Yvelise Ferro; Valeria Migliaccio; Carmine Gazzaruso; Arturo Pujia
Journal:  Endocrine       Date:  2012-10-09       Impact factor: 3.633

4.  Effect of conjugated linoleic acid supplementation on quality of life in rectal cancer patients undergoing preoperative Chemoradiotherapy.

Authors:  Elnaz Faramarzi; Reza Mahdavi; Mohammad Mohammad-Zadeh; Behnam Nasirimotlagh; Sarvin Sanaie
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

5.  Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia.

Authors:  Raymond D Devine; Sabahattin Bicer; Peter J Reiser; Markus Velten; Loren E Wold
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-19       Impact factor: 4.733

6.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118.

Authors:  Eduardo J Salustiano; Matheus L Dumas; Gabriel G Silva-Santos; Chaquip D Netto; Paulo R R Costa; Vivian M Rumjanek
Journal:  Invest New Drugs       Date:  2016-05-18       Impact factor: 3.850

Review 8.  The role of inflammatory pathways in cancer-associated cachexia and radiation resistance.

Authors:  Aaron Laine; Puneeth Iyengar; Tej K Pandita
Journal:  Mol Cancer Res       Date:  2013-06-20       Impact factor: 5.852

9.  Pyrroloquinoline quinone attenuates cachexia-induced muscle atrophy via suppression of reactive oxygen species.

Authors:  Tongtong Xu; Xiaoming Yang; Changyue Wu; Jiaying Qiu; Qingqing Fang; Lingbin Wang; Shu Yu; Hualin Sun
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

10.  HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders.

Authors:  Emmanuel L Gautier; Marit Westerterp; Neha Bhagwat; Serge Cremers; Alan Shih; Omar Abdel-Wahab; Dieter Lütjohann; Gwendalyn J Randolph; Ross L Levine; Alan R Tall; Laurent Yvan-Charvet
Journal:  J Exp Med       Date:  2013-01-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.